A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma

被引：0
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [31] Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
    Mondello, Patrizia
    Mian, Michael
    Arrigo, Carmela
    Pitini, Vincenzo
    SPRINGERPLUS, 2014, 3 : 1 - 5
  • [32] Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Uchida, Toshiki
    Ohmachi, Ken
    Matsumoto, Yosuke
    Tobinai, Kensei
    CANCER SCIENCE, 2011, 102 (09) : 1687 - 1692
  • [33] A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma
    Warsch, Sean
    Hosein, Peter J.
    Maeda, Lauren S.
    Alizadeh, Ash A.
    Lossos, Izidore S.
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1299 - 1305
  • [34] Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
    Martin, Peter
    Cohen, Jonathon B.
    Wang, Michael
    Kumar, Anita
    Hill, Brian
    Villa, Diego
    Switchenko, Jeffrey M.
    Kahl, Brad
    Maddocks, Kami
    Grover, Natalie S.
    Qi, Keqin
    Parisi, Lori
    Daly, Katherine
    Zhu, Angeline
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 541 - +
  • [35] Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
    Roider, Tobias
    Dietrich, Sascha
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (11) : 1811 - 1812
  • [36] Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission
    Chakhachiro, Zaher I.
    Saliba, Rima M.
    Okoroji, Grace-Julia
    Korbling, Martin
    Alousi, Amin M.
    Betul, Oran
    Anderlini, Paolo
    Ciurea, Stefan O.
    Popat, Uday
    Champlin, Richard
    Samuels, Barry I.
    Medeiros, L. Jeffrey
    Bueso-Ramos, Carlos
    Khouri, Issa F.
    CANCER, 2013, 119 (18) : 3318 - 3325
  • [37] A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma
    Paikaray, Sushant Kumar
    Gogia, Ajay
    Kumar, Lalit
    Sharma, Atul
    Biswas, Ahit Agni
    Vishnubhatla, Sreeniwas
    Mallick, Soumya
    INDIAN JOURNAL OF CANCER, 2023, 60 (04) : 501 - 504
  • [38] A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
    Cheson, Bruce D.
    Crawford, Jeanette
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 528 - 533
  • [39] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [40] Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report
    Ettleson, Matthew
    Bongers, Kale S.
    Vitale, Kaitlyn
    Perissinotti, Anthony J.
    Phillips, Tycel
    Marini, Bernard L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 731 - 734
12345